A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/24/2004	EP1479666A1 Ester compound and medicinal use thereof
11/24/2004	EP1479402A1 Increased biocompatibility of implantable medical devices
11/24/2004	EP1479397A1 2,4,6-triamino-1,3,5-triazine derivative
11/24/2004	EP1479395A1 Modified factor VII
11/24/2004	EP1479394A1 The use of epidermal growth factor (EGF) for increasing weight gain in an animal
11/24/2004	EP1479389A1 Ready to use gemcitabine solutions
11/24/2004	EP1479388A1 Ready to use gemcitabin solution concentrates
11/24/2004	EP1479387A1 Remedies for glaucoma comprising bunazosin and prostaglandins
11/24/2004	EP1479386A1 Use of isoquinoline-derivatives for treating and preventing pigmentary disorders
11/24/2004	EP1479385A1 Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
11/24/2004	EP1479384A1 Fibrosis inhibitor
11/24/2004	EP1479383A1 Oral sustained release pharmaceutical composition
11/24/2004	EP1479382A1 Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
11/24/2004	EP1479381A1 Pharmaceutical dosage form comprising a solid solution
11/24/2004	EP1479380A1 Use of soaps such as magnesium stearate for increasing the release of drugs
11/24/2004	EP1479379A1 Dry liposomal PVP-iodine compositions
11/24/2004	EP1479374A1 Process for the cosmetic treatment of cutaneous erythema or skin redness
11/24/2004	EP1479373A1 Hair growth compositions and uses
11/24/2004	EP1479300A1 Amino acid powder and process for producing the same
11/24/2004	EP1479295A1 Use of naphtoquinone compounds for the preparation of biocidal compositions
11/24/2004	EP1478773A2 Methods for assessing and treating leukemia
11/24/2004	EP1478758A1 Polymorphisms in elastin, fibrillin, and related genes as predisposing to restenosis and to atherosclerosis
11/24/2004	EP1478731A1 Phenalenone derivatives, method for the production thereof and use of the same
11/24/2004	EP1478660A2 KAPPA−PVIIA−RELATED CONOTOXINS AS ORGAN PROTECTANTS
11/24/2004	EP1478656A2 Oligonucleotide compositions with enhanced efficiency
11/24/2004	EP1478653A1 Macrolides with antibacterial activity
11/24/2004	EP1478650A1 Novel boronate esters
11/24/2004	EP1478649A1 Novel cephalosporin compounds and process for preparing the same
11/24/2004	EP1478648A2 Phosphorus-containing compounds uses thereof
11/24/2004	EP1478646A1 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
11/24/2004	EP1478645A2 Quinolinone derivatives for treating cell proliferation related disorders
11/24/2004	EP1478640A1 Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
11/24/2004	EP1478639A1 Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
11/24/2004	EP1478636A1 Amorphous citalopram
11/24/2004	EP1478635A1 Process for the production of citalopram
11/24/2004	EP1478634A1 Furanone derivatives
11/24/2004	EP1478632A1 Substituted aryl alkenoic acid heterocyclic amides possessing pungent taste
11/24/2004	EP1478630A2 Process and intermediates for preparing phenylthiomethyl-thiazoles or -oxazoles
11/24/2004	EP1478629A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
11/24/2004	EP1478627A1 Method
11/24/2004	EP1478625A1 Processes and intermediates useful in preparing beta-3-adrenergic receptor agonists
11/24/2004	EP1478624A1 Chemical compounds
11/24/2004	EP1478622A1 Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n- 2 n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl -ethylpyrrolidine
11/24/2004	EP1478620A1 Phenethanolamine derivatives for treatment of respiratory diseases
11/24/2004	EP1478618A1 Polyamine compounds and compositions for use in conjunction with cancer therapy
11/24/2004	EP1478613A2 Substituted 10-aryl-11h-benzo[b]fluorenes and 7-aryl-5,6-dihydro-benz[a]anthracenes for selective effects on estrogen receptors
11/24/2004	EP1478438A1 Methods and compositions for the treatment of asthma and related disorders
11/24/2004	EP1478437A1 Acc inhibitors
11/24/2004	EP1478405A2 Beta-homolysine conjugates and their use as transport enhancer
11/24/2004	EP1478404A1 Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
11/24/2004	EP1478402A1 Preparation for oxidation-sensitive compounds and method for making same
11/24/2004	EP1478401A2 Compositions comprising dietary fat complexer and methods for their use
11/24/2004	EP1478400A1 Therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents
11/24/2004	EP1478399A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
11/24/2004	EP1478398A1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
11/24/2004	EP1478397A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
11/24/2004	EP1478396A1 Process for the preparation of a nutrient formulation
11/24/2004	EP1478389A1 Treatment for diseases of the eye, inner ear and central nervous system
11/24/2004	EP1478384A2 Method for increasing the survival of dopamine secreting cells
11/24/2004	EP1478380A2 Use of tyrosine kinase inhibitors for treating cns disorders
11/24/2004	EP1478377A1 A composition
11/24/2004	EP1478374A1 Formulations comprising psychotropic drugs and selenium
11/24/2004	EP1478373A1 Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12
11/24/2004	EP1478372A1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
11/24/2004	EP1478371A2 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/24/2004	EP1478370A1 Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases
11/24/2004	EP1478369A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
11/24/2004	EP1478368A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia
11/24/2004	EP1478367A2 Intraspinal continuous infusion of midazolam hydrochloride for the treatment of pain
11/24/2004	EP1478366A1 Pharmaceutical combinations of cox-2 inhibitors and opiates
11/24/2004	EP1478365A1 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
11/24/2004	EP1478364A2 Selective antibacterial agents
11/24/2004	EP1478363A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
11/24/2004	EP1478362A1 A combination treatment for acute myocardial infarction
11/24/2004	EP1478361A2 Arylsulfone derivatives
11/24/2004	EP1478360A1 Agents which interact with a serotonin transporter for the treatment of cancer
11/24/2004	EP1478359A1 Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
11/24/2004	EP1478358A1 Aryl ureas with angiogenesis inhibiting activity
11/24/2004	EP1478357A2 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
11/24/2004	EP1478356A2 Therapeutic compounds
11/24/2004	EP1478355A2 Antitumor compositions containing taxane derivatives
11/24/2004	EP1478354A2 Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
11/24/2004	EP1478353A1 Sustained release pharmaceutical composition
11/24/2004	EP1478352A1 Pharmaceutical dosage form and method for the production thereof
11/24/2004	EP1478347A1 Dry granulated formulations of azithromycin
11/24/2004	EP1478343A2 Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
11/24/2004	EP1478342A1 Sterile filtered nanoparticule formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
11/24/2004	EP1478340A1 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
11/24/2004	EP1478339A1 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
11/24/2004	EP1478338A1 Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof
11/24/2004	EP1478337A1 System for transvaginal drug delivery
11/24/2004	EP1478329A1 Orally administrable composition for the photoprotection of the skin
11/24/2004	EP1478327A2 Method of reducing and treating uvb-induced immunosuppression
11/24/2004	EP1478323A2 Combinatorial anti-acne compositions
11/24/2004	EP1478322A2 Beta-2'-OR 3'-HALONUCLEOSIDES
11/24/2004	EP1478276A2 Novel targeted compositions for diagnostic and therapeutic use
11/24/2004	EP1478242A1 Pet food composition for skin photoprotection
11/24/2004	EP1478236A2 Targeted retrograde gene delivery to motor neurons
11/24/2004	EP1478228A2 Anti-microbial systems and methods
11/24/2004	EP1420799A4 Use of atazanavir in hiv therapy

1 ... 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 4899 4900 4901 4902 ... 7860